ADC therapy is well established in the AML disease area, with reapproval of CD33-targeting Mylotarg (gemtuzumab ozogamycin) for relapsed or refractory AML73 and with many more ADCs in development74. This evidence concerns the gene CD33 and acute myeloid leukemia.